|

Cladribine (CLAD) Clinical Trials

2 actively recruiting trials across 2 locations

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Stanford University1
  • M.D. Anderson Cancer Center1

Indications

  • Cancer2
  • Mutations1
  • IDH1-Mutated Malignancies1
  • Relapsed Acute Myeloid Leukemia1
  • Targeted Therapy1

Palo Alto, California1 trial

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Stanford University

Phase 1/2

Houston, Texas1 trial

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

MD Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.